Difference between revisions of "Team:CGU Taiwan"
Justine0325 (Talk | contribs) |
|||
| (67 intermediate revisions by 2 users not shown) | |||
| Line 29: | Line 29: | ||
height: 115px; | height: 115px; | ||
font-family: Corbel; | font-family: Corbel; | ||
| − | |||
overflow: visible; | overflow: visible; | ||
z-index: +1; | z-index: +1; | ||
| Line 56: | Line 55: | ||
.header-subnav { | .header-subnav { | ||
float: none; | float: none; | ||
| − | background: | + | background: #0D014D; |
position: absolute; | position: absolute; | ||
text-align: center; | text-align: center; | ||
| Line 99: | Line 98: | ||
left: 0px; | left: 0px; | ||
width: 100%; | width: 100%; | ||
| − | height: | + | height: 30%; |
font-family: Corbel; | font-family: Corbel; | ||
} | } | ||
| Line 129: | Line 128: | ||
background-position:10px; | background-position:10px; | ||
background-size:9%; | background-size:9%; | ||
| + | margin-bottom:-20%; | ||
} | } | ||
.list2 li { | .list2 li { | ||
| Line 142: | Line 142: | ||
background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg); | background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg); | ||
background-repeat:no-repeat; | background-repeat:no-repeat; | ||
| − | background-position: | + | background-position:5%; |
| − | background-size: | + | background-size:2%; |
margin-bottom:-10%; | margin-bottom:-10%; | ||
} | } | ||
| Line 168: | Line 168: | ||
<body> | <body> | ||
<a name='anchor1'></a> | <a name='anchor1'></a> | ||
| − | <div class="top"><img style="margin-top: | + | <div class="top"> |
| + | <img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg"> | ||
</div> | </div> | ||
| Line 184: | Line 185: | ||
</div> | </div> | ||
</header> | </header> | ||
| − | + | <br><br><br> | |
<div> | <div> | ||
| − | <video width="100%" height="700px" controls autoplay> | + | <br><br><br><br> |
| − | <source src="https://static.igem.org/mediawiki/2016/ | + | <video margin-top="5%" width="100%" height="700px" controls autoplay> |
| + | <source src="https://static.igem.org/mediawiki/2016/4/41/CGU_Taiwan--video4.mp4" type="video/mp4"> | ||
</video> | </video> | ||
</div> | </div> | ||
| Line 194: | Line 196: | ||
<div class="mid"> | <div class="mid"> | ||
<div style="font-size:60px;color:#140731;text-decoration:none;margin-left:45%;"> | <div style="font-size:60px;color:#140731;text-decoration:none;margin-left:45%;"> | ||
| + | <br><br><br><br> | ||
Abstract | Abstract | ||
</div> | </div> | ||
<br></br> | <br></br> | ||
<br></br> | <br></br> | ||
| − | <b style="color:black;font-size: | + | <b style="color:black;font-size:25px;margin-left:10%;">Leijuvant- A Revolutionary Choice of Vaccine Helper</b><br><br> |
<div style="color:black;font-size:18px;margin-left:10%;text-align:justify;"> | <div style="color:black;font-size:18px;margin-left:10%;text-align:justify;"> | ||
For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public. | For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public. | ||
| Line 205: | Line 208: | ||
</div> | </div> | ||
| − | <div class="mid2" style="background-color:#d0d0d0;top: | + | <div class="mid2" style="background-color:#d0d0d0;top:130%;"> |
<div style="font-size:60px;color:#140731;margin-left:35%;margin-top:2%;"> | <div style="font-size:60px;color:#140731;margin-left:35%;margin-top:2%;"> | ||
| − | Start | + | <br> |
| + | Start the Journey | ||
</div> | </div> | ||
<br></br> | <br></br> | ||
<br></br> | <br></br> | ||
| − | <a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height: | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:10%;" src="https://static.igem.org/mediawiki/2016/4/40/CGU_Taiwan--t4.jpg"> |
| − | <h2 style="font-size:35px;color:#140731;position:absolute;left:15%;top:490px;z-index:+1;text-decoration:none;">PROJECT</h2> | + | <h2 style="font-size:35px;color:#140731;position:absolute;left:15%;top:490px;z-index:+1;text-decoration:none;">PROJECT</h2></a> |
| − | <a href="http://facebook.com/igemcgu"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height: | + | <a href="http://facebook.com/igemcgu"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:38%;" src="https://static.igem.org/mediawiki/2016/c/cd/CGU_Taiwan--macrophage.jpg"> |
| − | <h3 style="font-size:35px;color:#140731;position:absolute;left:45%;top:490px;text-decoration:none;">NEWS</h3> | + | <h3 style="font-size:35px;color:#140731;position:absolute;left:45%;top:490px;text-decoration:none;">NEWS</h3></a> |
| − | <a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height: | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:66%;" src="https://static.igem.org/mediawiki/2016/7/7c/CGU_Taiwan--HA.jpg"> |
| − | <h4 style="font-size:35px;color:#140731;position:absolute;left:72%;top:490px;text-decoration:none;">RESULTS</h4> | + | <h4 style="font-size:35px;color:#140731;position:absolute;left:72%;top:490px;text-decoration:none;">RESULTS</h4></a> |
</div> | </div> | ||
| − | <div class="end" style="top: | + | <div class="end" style="top:190%;"> |
<div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;"> | <div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;"> | ||
Chang Gung University | Chang Gung University | ||
| Line 228: | Line 232: | ||
<br> | <br> | ||
TEL: +886-3-2118800 FAX:+886-3-2118700 | TEL: +886-3-2118800 FAX:+886-3-2118700 | ||
| − | <img src="https://static.igem.org/mediawiki/2016/ | + | <img src="https://static.igem.org/mediawiki/2016/e/eb/CGU_Taiwan--sponsor0.6.jpg" style="position:absolute;top:0%;margin-left:25%;width:35%;height:45%;margin-top:3%;"> |
</div> | </div> | ||
</div> | </div> | ||
<br><br><br><br><br> | <br><br><br><br><br> | ||
| − | <div class="end2" style="top: | + | <div class="end2" style="top:210%;"> |
| − | <br><br> | + | <br> |
| + | <ul class="list3" class="margin-left:1%;margin-top:2%;"> | ||
| + | <li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li> | ||
| + | </ul> | ||
| + | <br> | ||
<div class="sitemap" style="margin-left:5%;"> | <div class="sitemap" style="margin-left:5%;"> | ||
<br> | <br> | ||
| − | <b style="color:white;font-size: | + | <b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br> |
<br><br> | <br><br> | ||
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:50%;height:90%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg"> | <img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:50%;height:90%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg"> | ||
</div> | </div> | ||
| − | |||
| − | <div class="sitemap" style="margin-left: | + | <div class="sitemap" style="margin-left:22%;margin-top:-1%;"> |
<ul class="list" class="margin-left:5%;"> | <ul class="list" class="margin-left:5%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a> |
</ul> | </ul> | ||
</div> | </div> | ||
| Line 255: | Line 262: | ||
<div class="sitemap" style="margin-left:40%;margin-top:-2%;"> | <div class="sitemap" style="margin-left:40%;margin-top:-2%;"> | ||
<ul class="list" class="margin-left:5%;"> | <ul class="list" class="margin-left:5%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a> |
| + | <br><br> | ||
<ul class="list2" class="margin-left:6%;margin-top:50%;"> | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a> |
<br><br> | <br><br> | ||
</ul> | </ul> | ||
| Line 269: | Line 277: | ||
<div class="sitemap" style="margin-left:55%;margin-top:-3.5%;"> | <div class="sitemap" style="margin-left:55%;margin-top:-3.5%;"> | ||
<ul class="list" class="margin-left:5%;"> | <ul class="list" class="margin-left:5%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a> |
| + | <br><br> | ||
<ul class="list2" class="margin-left:6%;margin-top:50%;"> | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a> |
</ul> | </ul> | ||
</ul> | </ul> | ||
| Line 281: | Line 290: | ||
<div class="sitemap" style="margin-left:75%;margin-top:-3.5%;"> | <div class="sitemap" style="margin-left:75%;margin-top:-3.5%;"> | ||
<ul class="list" class="margin-left:5%;"> | <ul class="list" class="margin-left:5%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a> |
| + | <br><br> | ||
<ul class="list2" class="margin-left:6%;"> | <ul class="list2" class="margin-left:6%;"> | ||
| − | <li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li> | + | <li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a> |
</ul> | </ul> | ||
</ul> | </ul> | ||
| − | <ul class="list" class="margin-left:1 | + | <ul class="list" class="margin-left:1%;"> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a> |
| + | <br><br> | ||
<ul class="list2" class="margin-left:6%;margin-top:-5%;"> | <ul class="list2" class="margin-left:6%;margin-top:-5%;"> | ||
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a> |
| − | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a> |
| + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a> | ||
</ul> | </ul> | ||
</ul> | </ul> | ||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
Latest revision as of 07:04, 2 December 2016
Abstract
Leijuvant- A Revolutionary Choice of Vaccine Helper
For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.
Chang Gung University
No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan (R.O.C.)
TEL: +886-3-2118800 FAX:+886-3-2118700
TEL: +886-3-2118800 FAX:+886-3-2118700
